Public notice

The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, eLife

관리자 │ 2023-01-17

HIT

670

The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, eLife (June 26, 2020).



The study, titled, “3,6'-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation,” may be found here (https://elifesciences.org/articles/54726).


Previous Post There is no previous post.
Next Post Research on the immunomodulatory imide drugs development under the Cooperative R...